Drug intelligence / Profile preview

PSIL-025

Development stage: Preclinical
Lead developer: Psilera
Modality: Small Molecules

Overview

PSIL-025 is a small molecule neuroplastogen being developed by Psilera for the treatment of mood-related disorders. It is part of Psilera's proprietary platform focused on developing non-hallucinogenic derivatives of psychedelic compounds. These compounds are designed to promote neuroplasticity—the brain's ability to reorganize and form new neural connections—without the intense psychedelic effects typically associated with traditional psychedelics like psilocybin or DMT. PSIL-025 is currently in the lead optimization stage of preclinical development.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on PSIL-025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSIL-025.